Rising cancer antigen 125 level and the type and timing of treatment for recurrent ovarian cancer: A clinical dilemma, but what would women do?

International Journal of Gynecological Cancer

Volumn 19, Issue 6, 2009, Pages 1037-1046

  Harrison, James D ^a,c   Juraskova, Ilona ^b   Anderson, Caroline ^c   Nattress, Kathryn ^c   Beale, Philip ^c   Lopez, Anna Lena ^b   Carter, Jonathan ^c  

^a Surgical Outcomes Research Centre   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

CA 125; Ovarian cancer; Patient treatment preference; Recurrent disease; Treatment decision making

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CLINICAL ARTICLE; COPING BEHAVIOR; DRUG EFFICACY; EARLY INTERVENTION; FEMALE; HUMAN; LIFE EXPECTANCY; OVARY CANCER; PATIENT ATTITUDE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOLOGICAL WELL BEING; RATING SCALE; RECURRENT CANCER; SCORING SYSTEM; UNCERTAINTY;

ANTINEOPLASTIC PROTOCOLS; CA-125 ANTIGEN; DECISION MAKING; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATIENT EDUCATION AS TOPIC; PATIENT PREFERENCE; QUESTIONNAIRES; RECURRENCE; SENTINEL SURVEILLANCE; SOCIAL CLASS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 70349233895     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a83d0b     Document Type: Article

References (30)

1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519-2529.
2. Wilder JL, Pavlik E, Straughn JM, et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol. 2003;89:233-235.
3. Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising CA-125 levels within the normal range. J Clin Oncol. 2005;23:9338-9343.
4. Rustin GJS, Marples M, Nelstrop AE, et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001;19:4054-4057.
5. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA-125: a North Thames ovary study group. Ann Oncol. 1996;7:361-364.
6. Goonewardene TI, Hall MR, Rustin GJS. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007;8:813-821.
7. Harrison JD, Carter J, Young JM, et al. Difficult clinical decisions in gynaecologic oncology: identifying priorities for future research. Int J Gynecol Cancer. 2006;16:1-7.3.
8. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-145.
9. Medical Research Council and EORTC. A randomised trial in relapsed ovarian cancer: early treatment based on CA-125 levels alone versus delayed treatment based on conventional clinical indicatorsVMRC OV05 & EORTC/GCCG 55955. Available at: http://www.ctu.mrc.ac.uk/ studies/OV05.asp. Accessed July 21, 2008.
10. Parker PA, Kudelka A, Basen-Engquist K, et al. The associations between knowledge, CA-125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecol Oncol. 2006;100:495-500.
11. Ferell B, Cullinan CA, Ervin K, et al. Perspectives on the impact of ovarian cancer: women's views of quality of life. Oncol Nurs Forum. 2005;32:1143-1149.
12. Howell D, Fitch MI, Deane KA. Impact of ovarian cancer perceived by women. Cancer Nurs. 2003;26:1-9.
13. Stigglebout AM, de Haas CJM. Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol. 2001:220-230.
14. Donovan KA, Greene PG, Shuster JL, et al. Treatment preferences in ovarian cancer. Gynecol Oncol. 2002;86:200-211.
15. Penson RT, Dignan F, Seiden MV, et al. Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol. 2004;94:427-435.
16. Edwards P, Roberts I, Clarke M, et al. Increasing response rates to postal questionnaires: systematic review. BMJ. 2002;324:1183-1191.
17. Young JM, Solomon MJ, Harrison JD, et al. Measuring patient preference and surgeon choice. Surgery. 2008;143:582-588.
18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
19. Horowitz M,Wilner M, AlvarezW. Impact of events scale: a measure of subjective stress. Psychosom Med. 1979;41:209-218.
20. Broadbent E, Petrie KJ, Main J, et al. The brief illness perception questionnaire. J Psychosom Res. 2006;60:631-637.
21. Weinman J, Petrie KJ, Moss-Morris R, et al. The Illness Perception Questionnaire: a new method for assessing illness perceptions. Psychol Health. 1996;11:431-446.
22. Charles C, Redko C, Whelan T, et al. Doing nothing is no choice: lay constructions of treatment decision-making among women with early-stage breast cancer. Sociol Health Illn. 1998;20:71-95.
23. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin with topetecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1-8.
24. ten Bokkel Huinink W, Lane SR, Ross GA. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian cancer. Ann Oncol. 2004;15:100-103.
25. Doyle C, Crump M, Pintilie M, et al. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced cancer. J Clin Oncol. 2001;19:5:1266-1274.
26. Harrison JD, Solomon MJ, Young JM, et al. Patient and clinician preferences for surgical and adjuvant treatment for rectal cancer. Arch Surg. 2008;143:389-394.
27. Carroll BT, Kathol RG, Noyes R, et al. Screening for depression and anxiety in cancer patients using the hospital anxiety and depression scale. Gen Hosp Psychiatry. 1993;15:69-74.
28. Norton TR, Manne SL, Rubin S, et al. Prevalence and predictors of psychological distress among women with ovarian cancer. J Clin Oncol. 2004;22:919-926.
29. Junghans C, Feder G, Hemingway H, et al. Recruiting patients to medical research: double blind randomised trial of "opt-in" versus "opt-out strategies. BMJ. 2005;331:940.
30. O'Connor AM, Stacey D, Entwistle V, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2003;1:CD001431.